These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32561345)

  • 1. Novel biomarkers for lysosomal storage disorders: Metabolomic and proteomic approaches.
    Elmonem MA; Abdelazim AM
    Clin Chim Acta; 2020 Oct; 509():195-209. PubMed ID: 32561345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass spectrometry-based proteomics in neurodegenerative lysosomal storage disorders.
    Li W; Cologna SM
    Mol Omics; 2022 May; 18(4):256-278. PubMed ID: 35343995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highlights on Genomics Applications for Lysosomal Storage Diseases.
    La Cognata V; Guarnaccia M; Polizzi A; Ruggieri M; Cavallaro S
    Cells; 2020 Aug; 9(8):. PubMed ID: 32824006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Lysosomal Storage Disorders with an Emphasis on Mass Spectrometry.
    Mashima R; Okuyama T; Ohira M
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32295281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease.
    Aerts JM; van Breemen MJ; Bussink AP; Ghauharali K; Sprenger R; Boot RG; Groener JE; Hollak CE; Maas M; Smit S; Hoefsloot HC; Smilde AK; Vissers JP; de Jong S; Speijer D; de Koster CG
    Acta Paediatr; 2008 Apr; 97(457):7-14. PubMed ID: 18339181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomic Studies of Lipid Storage Disorders, with Special Reference to Niemann-Pick Type C Disease: A Critical Review with Future Perspectives.
    Percival BC; Gibson M; Wilson PB; Platt FM; Grootveld M
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum protein profile analysis in lysosomal storage disorders patients.
    López de Frutos L; García-González E; García-Rodríguez B; González-Irazabal Y; Lahoz C; Irún P; Cebolla JJ; Giraldo P
    Clin Chim Acta; 2020 Nov; 510():430-436. PubMed ID: 32745579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening.
    Kingma SD; Bodamer OA; Wijburg FA
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):145-57. PubMed ID: 25987169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial Dysfunction and Neurodegeneration in Lysosomal Storage Disorders.
    Plotegher N; Duchen MR
    Trends Mol Med; 2017 Feb; 23(2):116-134. PubMed ID: 28111024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of acid alpha-glucosidase protein: evaluation as a screening marker for Pompe disease and other lysosomal storage disorders.
    Umapathysivam K; Whittle AM; Ranieri E; Bindloss C; Ravenscroft EM; van Diggelen OP; Hopwood JJ; Meikle PJ
    Clin Chem; 2000 Sep; 46(9):1318-25. PubMed ID: 10973860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal storage disorders - challenges, concepts and avenues for therapy: beyond rare diseases.
    Marques ARA; Saftig P
    J Cell Sci; 2019 Jan; 132(2):. PubMed ID: 30651381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the lysosomal hydrolase activity in blood collected on filter paper, an alternative to screen high risk populations.
    Castilhos CD; Mezzalira J; Goldim MP; Daitx VV; Garcia Cda S; Andrade CV; Breier AC; Cé J; Mello AS; Coelho JC
    Gene; 2014 Feb; 536(2):344-7. PubMed ID: 24342658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.
    Nascimbeni F; Dionisi Vici C; Vespasiani Gentilucci U; Angelico F; Nobili V; Petta S; Valenti L;
    Dig Liver Dis; 2020 Apr; 52(4):359-367. PubMed ID: 31902560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Models to study basic and applied aspects of lysosomal storage disorders.
    Gaudioso Á; Silva TP; Ledesma MD
    Adv Drug Deliv Rev; 2022 Nov; 190():114532. PubMed ID: 36122863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders.
    Gelb MH; Turecek F; Scott CR; Chamoles NA
    J Inherit Metab Dis; 2006; 29(2-3):397-404. PubMed ID: 16763908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein Non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in Macrophages.
    van der Lienden MJC; Gaspar P; Boot R; Aerts JMFG; van Eijk M
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30586924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are there useful biochemical markers of disease activity in lysosomal storage diseases?
    Winchester B
    J Inherit Metab Dis; 2001; 24 Suppl 2():52-6; discussion 45-6. PubMed ID: 11758679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From bedside to cell biology: a century of history on lysosomal dysfunction.
    Coutinho MF; Matos L; Alves S
    Gene; 2015 Jan; 555(1):50-8. PubMed ID: 25275857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders.
    Piraud M; Pettazzoni M; Lavoie P; Ruet S; Pagan C; Cheillan D; Latour P; Vianey-Saban C; Auray-Blais C; Froissart R
    J Inherit Metab Dis; 2018 May; 41(3):457-477. PubMed ID: 29556840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.